Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lypressin

FDA-approved product (solution, nasal), marketed as Diapid.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Lypressin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Lypressin. Its therapeutic class is shown instead.

WHO therapeutic group
Vasopressin and analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA63.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli55.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae48.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lypressin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lypressin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Short Course Terlipressin for Control of Acute Variceal Bleeding

    NCT00369694 · start 2006-08

    Registered record
    Registry ID
    NCT00369694
    Conditions
    Hemorrhage; Esophageal Varices; Portal Hypertension
    Interventions
    Terlipressin; Terlipressin & then Dummy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-08
    Completion
    2008-08
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHemorrhage; Esophageal Varices; Portal Hypertension
    InterventionTerlipressin; Terlipressin & then Dummy
    PhasePhase 4
    Registry statusCompleted

  • Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome

    NCT00742339 · start 2005-05

    Registered record
    Registry ID
    NCT00742339
    Conditions
    Cirrhosis; Hepatorenal Syndrome
    Interventions
    Terlipressin plus albumin; Midodrine plus octreotide plus human albumin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2005-05
    Completion
    2013-10
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhosis; Hepatorenal Syndrome
    InterventionTerlipressin plus albumin; Midodrine plus octreotide plus human albumin
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • Renal and Cardiovascular Effects of Terlipressin in Patients With Cirrhosis and Ascites

    NCT00115947 · start 2004-12

    Registered record
    Registry ID
    NCT00115947
    Conditions
    Cirrhosis; Ascites
    Interventions
    Terlipressin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2004-12
    Completion
    2006-01
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhosis; Ascites
    InterventionTerlipressin
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1

    NCT00089570 · start 2004-06

    Registered record
    Registry ID
    NCT00089570
    Conditions
    Hepatorenal Syndrome
    Interventions
    terlipressin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-06
    Completion
    2006-09
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatorenal Syndrome
    Interventionterlipressin; Placebo
    PhasePhase 3
    Registry statusCompleted

  • The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed

    NCT00534677 · start 2004-05

    Registered record
    Registry ID
    NCT00534677
    Conditions
    Portal Hypertension; Cirrhosis; Hematemesis; Melena
    Interventions
    Terlipressin; Octreotide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-05
    Completion
    2005-07
    Enrolment
    320

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPortal Hypertension; Cirrhosis; Hematemesis; Melena
    InterventionTerlipressin; Octreotide
    PhasePhase 4
    Registry statusCompleted